Navigation Links
Avitar Reports Third Quarter Financial Results for Fiscal 2007
Date:8/19/2007

CANTON, Mass., Aug. 14 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC Bulletin Board: AVTI) today announced financial results for the three and nine months ended June 30, 2007.

For the quarter ended June 30, 2007, Avitar reported revenues of $779,000 from continuing operations compared to $1,202,000 from continuing operations for the quarter ended June 30, 2006. The operating loss from continuing operations amounted to $597,000 versus $696,000. The net income was $301,000, or $0.01 per basic share and $0.00 per diluted share, for the quarter ended June 30, 2007 compared with net loss of $1,329,000, or $0.31 per share for the quarter ended June 30, 2006. The reduction in net loss for the quarter ended June 30, 2007 compared to the quarter ended June 30, 2006 resulted primarily from an increase in non-cash income from the change in the fair market value of derivative securities and warrants of $1,062,000, a decrease in operating expenses of $522,000 and lower interest and financing costs related to short-term and long-term borrowings of $462,000; offset in part by a reduction in sales of $423,000.

Revenues from continuing operations for the first nine months of fiscal 2007 were $2,440,000 compared to $3,162,000 from continuing operations for the nine months ended June 30, 2006. The operating loss from continuing operations amounted to $2,136,000 versus $2,293,000. The net loss was $1,542,000 or $0.08 per share, for the nine months ended June 30, 2007 compared with net loss of $3,256,000, or $0.78 per share, for the nine months ended June 30, 2006. The change in net loss for the nine months ended June 30, 2007 compared to the corresponding period of Fiscal 2006 resulted primarily from an increase in non-cash income from the change in the fair market value of derivative securities and warrants of $1,449,000, a decrease in operating expenses of $878,000 and lower interest and financing costs related to short-term and long-term borrowings of $204,000; offset in part by a reduction in sales of $722,000 and a decrease in income from discontinued operations of $96,000.

Peter P. Phildius, Chairman and CEO commented, "Our total revenue continues to be negatively impacted by the decline in Hydrasorb sales through our U.S. distributor. We hope to improve the performance of our foam business in the coming quarters."

Mr. Phildius continued, "The diagnostic business, however, is showing continued improvement as our value proposition of random testing with oral fluid gains traction. An example of this change is the law recently passed in Hawaii which provides for oral fluid random testing for employers. We continue to work on further enhancing our product offerings and to be optimistic about this large market opportunity."

ABOUT AVITAR

Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of-abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM) an absorbent topical dressing for moderate to heavy exudating wounds. In the estimated $25 billion in vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at http://www.avitarinc.com.

Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.

Company Contact: Jay C. Leatherman, CFO

Avitar, Inc.

781-821-2440 x139

http://www.avitarinc.com

(Chart Follows)

Avitar, Inc.

Summary of Financial Results

(in thousands, except per share amounts)

Quarter Ended June 30, Nine Months Ended June 30,

2007 2006 2007 2006

Sales $779 $1,202 $2,440 $3,162

Operating Expenses:

Cost of Sales 562 875 1,803 2,245

Selling,

General and

Administrative 742 913 2,528 2,861

Research and

Development 72 110 245 349

Total Operating

Expenses 1,376 1,898 4,576 5,455

Operating Loss (597) (696) (2,136) (2,293)

Other Income (Expenses) 918 (607) 651 (1,003)

Income (Loss) From

Continuing

Operations 321 (1,303) (1,485) (3,296)

Discontinued

Operations:

Loss form the

Operations of

BJR (20) (26) (57) (80)

Income from the

Disposal of

USDTL - - - 120

Income (Loss)

from Discontinued

Operations (20) (26) (57) 40

Net Income (Loss) $301 $(1,329) $(1,542) $(3,256)

Basic Income (Loss)

Per Share From

Continuing

Operations $0.01 $(0.30) $(0.08) $(0.79)

Basic Income (Loss)

Per Share From

Discontinued

Operations - (0.01) - 0.01

Basic Income (Loss)

Per Share $0.01 $(0.31) $(0.08) $(0.78)

Diluted Income

(Loss) Per Share From

Continuing

Operations $- $(0.30) $(0.08) $(0.79)

Diluted Income

(Loss) Per Share From

Discontinued

Operations - (0.01) - 0.01

Diluted Income

(Loss) Per Share $- $(0.31) $(0.08) $(0.78)

Basic Weighted

Average Number of

Shares and Common

Equivalent Shares

Outstanding 28,025,823 4,480,981 19,726,267 4,301,369

Diluted Weighted

Average Number of

Shares and Common

Equivalent Shares

Outstanding 100,000,000 4,480,981 19,726,267 4,301,369

Selected Balance

Sheet Items: 06/30/2007

Cash 80

Total Assets 1,684

Total

Liabilities 7,709

Redeemable

Convertible and

Convertible

Preferred Stock 3,208

Stockholders'

Deficit (9,233)


'/>"/>
SOURCE Avitar, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/16/2017)... England , Aug. 16, 2017  Kingfisher Talent, the ... and leadership development, and Virdis Group, global executive search specialists ... alliance that enables clients to leverage the expertise and reach ... our clients here in the Boston ... population of leadership talent throughout the US, Canada ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , a ... announces the launch of the new NHS Agile biosensor chip . The ... for a wide range of molecules, including small and large molecules, peptides, proteins, ...
(Date:8/15/2017)... ... 2017 , ... Kenall, a leader in sealed solid-state lighting, ... sealed and perform efficiently for years. The downlights are ideal for a variety ... such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical processing ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):